Completed PHASE1 INTERVENTIONAL 2-arm NCT00664170

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

Sponsor: Mast Therapeutics, Inc.

Updated 7 times since 2017 Last updated: May 27, 2009 Started: Apr 30, 2008 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Cancer and is currently completed. Mast Therapeutics, Inc. leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mast Therapeutics, Inc.

Data source: Mast Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Buenos Aires, Argentina , Concepción, Argentina , La Jolla, United States , Mendoza, Argentina , Middletown, United States , Muscle Shoals, United States , Rosario, Argentina , Salta, Argentina , San Miguel de Tucumán, Argentina , Santa Fe, Argentina and 2 more locations